drugset
drugset / Trial / NCT05747924

Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT05747924 ↗

Phase 1/2 Completed 90 enrolled Avidity Biosciences, Inc.
RandomizedSequentialQuadruple-blindTreatment

Summary

A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)

Timeline

Start
2023-04-04
Primary completion
2026-03-18
Completion
2026-03-20

Drugs

EvaluationDrugModalityDoseRoute
Subject AOC 1020 Unknown — Intravenous

Indications

facioscapulohumeral muscular dystrophy 1 facioscapulohumeral muscular dystrophy 2 fibromuscular dysplasia frontometaphyseal dysplasia 2 hypogonadotropic hypogonadism 24 without anosmia